Big Pharma · Metabolic · United States

AstraZeneca — Metabolic in United States

OncologyRare DiseaseImmunologyCardiometabolic
Commission a AstraZeneca report

AstraZeneca in United States — Metabolic: the full competitive set, and the 1 AXLRx report covering them with market-access, payer and competitive detail, every figure verified to a live source.

All areas OncologyRare DiseaseMetabolicPulmonology
Market: All United States
Market access — United States

Tagrisso dominant in first-line EGFR+ NSCLC; Alexion complement franchise (Ultomiris/Soliris) holds strong specialty access.

AXLRx reports featuring AstraZeneca — Metabolic in United States
Type 2 Diabetes
CI
CI Metabolic CI TeamLaunch Lead

US Type 2 Diabetes Competitive Intelligence

Tirzepatide takes 41% of new GLP-1 starts; SELECT CV indication and IRA negotiation reshape US formulary access.

US In-Market Read report →